Taris Biomedical (Lexington, MA) a clinical-stage specialty pharmaceutical company focused on bladder diseases in pain, inflammation, oncology and incontinence, closed a $18.3M Series B financing. Participants include Third Rock Ventures, Flagship Ventures, Flybridge Capital Partners and Polaris Venture Partners.